Semaglutide and Muscle Loss in Older Adults: What the 2025-2026 Sarcopenia DataShow

Semaglutide lowers glucose and produces significant weight loss, but in older adults the scale can hide a second change: loss of muscle mass and function. A 2025 retrospective cohort study found that semaglutide-treated patients age 65 and older experienced significantly greater muscle loss over 24 months than matched controls, with appendicular skeletal muscle mass index falling by 0.39 kg/m² in women and 0.26 kg/m² in men (Drug Design, Development and Therapy, 2025).

Key Takeaways

• A 24-month study of 220 semaglutide-treated adults age 65 and older found significantly greater muscle mass and strength decline compared with 212 matched controls (Drug Design, Development and Therapy, 2025).
• Semaglutide dose, baseline muscle mass, and gait speed were independent predictors of accelerated muscle loss.
• Resistance training and optimized protein intake are the primary strategies clinicians recommend to protect lean tissue during therapy.

Why Is Older Age a Risk Factor?

Sarcopenia, the age-related loss of muscle mass and strength, typically begins after age 30 at a rate of 0.1% to 0.5% per year. When semaglutide produces rapid weight loss, a portion of that loss comes from lean tissue. In the 2025 study, sarcopenia prevalence was 27.7% at baseline, and semaglutide-treated patients showed cumulative appendicular skeletal muscle mass index loss that was significantly greater than controls from month 12 onward (Drug Design, Development and Therapy, 2025).

Citation capsule: A 2025 retrospective cohort study of older adults with type 2 diabetes found that semaglutide treatment was associated with accelerated muscle loss and functional decline over 24 months, particularly at higher doses, with baseline sarcopenia status emerging as a key vulnerability (Drug Design, Development and Therapy, 2025).

Does Semaglutide Cause Muscle Loss, or Is It Just Weight Loss?

The evidence is mixed. STEP and SURMOUNT trial data show that roughly 25% to 39% of total weight lost on semaglutide can be lean mass, depending on the population and dose (Peptide Nerds, 2026). Some analyses suggest tirzepatide may produce a more favorable fat-to-lean mass ratio, but head-to-head data are limited. The 2025 cohort study is notable because it measured functional outcomes—grip strength and gait speed—not just body composition, and found decline in the semaglutide group (Drug Design, Development and Therapy, 2025).

What Does This Mean for Your Prescription?

It does not mean older adults should avoid semaglutide. It means the risk-benefit conversation should include muscle protection strategies from the outset. Diabetes UK and the American Diabetes Association note that resistance training and protein optimization can substantially blunt lean mass loss during active weight loss (Diabetes UK, 2025).

Citation capsule: A 2025 integrative review of clinical evidence concluded that semaglutide accelerates sarcopenia risk in older adults with type 2 diabetes, with higher doses, lower baseline muscle mass, and slower gait speed predicting greater loss, and called for systematic investigation of nutritional supplementation and targeted exercise (ResearchGate, 2026).

Practical Steps to Preserve Muscle

Aim for 1.2 to 1.6 grams of protein per kilogram of body weight daily, spread across meals. Add resistance training two to three times weekly, focusing on compound movements that protect functional strength. Track grip strength and walking speed, not just weight, because muscle loss can happen even when the scale moves in the right direction (Peptide Nerds, 2026).

Frequently Asked Questions

Should I stop semaglutide if I am over 65?

Not without talking to your prescriber. The cardiovascular and glycemic benefits are real. The goal is to add muscle-protecting strategies, not necessarily to stop therapy (Diabetes UK, 2025).

How do I know if I am losing muscle?

If your weight is dropping but your strength is dropping faster, that is a warning sign. Ask for body composition testing or functional assessments such as gait speed and grip strength (Drug Design, Development and Therapy, 2025).

Does this apply to tirzepatide too?

The same concern exists for all GLP-1-based therapies that produce rapid weight loss in older adults. Head-to-head comparisons are limited, but the mechanism of lean mass loss during caloric deficit applies broadly (Peptide Nerds, 2026).

Is muscle loss reversible?

Some loss is reversible with resistance training and adequate nutrition once weight stabilizes. The priority is to minimize the loss during the active weight-loss phase (Diabetes UK, 2025).

Conclusion

Semaglutide is a powerful tool for diabetes and weight management, but in older adults it can accelerate sarcopenia without countermeasures. The evidence does not call for avoiding the drug; it calls for pairing it with protein optimization and resistance training from day one. Muscle is the part of weight loss you cannot afford to lose.